Ultragenyx Pharmaceutical Inc. Files 8-K
Ticker: RARE · Form: 8-K · Filed: Nov 5, 2024 · CIK: 1515673
| Field | Detail |
|---|---|
| Company | Ultragenyx Pharmaceutical Inc. (RARE) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: UGNX
TL;DR
UGNX filed an 8-K on Nov 5th for financial updates.
AI Summary
Ultragenyx Pharmaceutical Inc. filed an 8-K on November 5, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signifies a formal update from Ultragenyx Pharmaceutical Inc. to the SEC regarding its financial condition and operations, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial information and does not indicate any immediate negative events.
Key Players & Entities
- Ultragenyx Pharmaceutical Inc. (company) — Registrant
- November 05, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 60 Leveroni Court (address) — Principal Executive Offices
- Novato, California (location) — Principal Executive Offices City and State
- 415-483-8800 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing by Ultragenyx Pharmaceutical Inc.?
The primary purpose of this 8-K filing is to report on Ultragenyx Pharmaceutical Inc.'s results of operations and financial condition, and to file financial statements and exhibits.
On what date was this 8-K filing reported?
The 8-K filing was reported on November 05, 2024.
In which state was Ultragenyx Pharmaceutical Inc. incorporated?
Ultragenyx Pharmaceutical Inc. was incorporated in Delaware.
What is the principal executive office address for Ultragenyx Pharmaceutical Inc.?
The principal executive office address is 60 Leveroni Court, Novato, California, 94949.
What is the telephone number listed for Ultragenyx Pharmaceutical Inc.?
The telephone number listed for Ultragenyx Pharmaceutical Inc. is 415-483-8800.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-11-05 16:06:50
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select
Filing Documents
- rare-20241105.htm (8-K) — 42KB
- rare-ex99_1.htm (EX-99.1) — 279KB
- img45776771_0.jpg (GRAPHIC) — 7KB
- 0000950170-24-121459.txt ( ) — 458KB
- rare-20241105.xsd (EX-101.SCH) — 23KB
- rare-20241105_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 5, 2024, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended September 30, 2024 (the " Press Release "). A copy of the Press Release is furnished herewith as Exhibit 99.1 The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 5, 2024. 104 The cover page from the Company's Current Report on Form 8-K dated November 5, 2024 formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx Pharmaceutical Inc. Date: November 5, 2024 By: /s/ Howard Horn Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy